Promising brain cancer drug combo study pulled before it started
NCT ID NCT06466798
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study aimed to test the safety of giving a combination of drugs (nivolumab plus either methotrexate or 5-azacytidine) directly into the fluid-filled spaces of the brain for people with recurrent brain tumors like medulloblastoma and ependymoma. The goal was to see if this direct delivery method could be safer and more effective than standard treatments. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.